中国现代药物应用
中國現代藥物應用
중국현대약물응용
CHINESE JOURNAL OF MODERN DRUG APPLICATION
2014年
8期
10-12
,共3页
阿卡波糖%急性冠脉综合征%颈动脉斑块%2型糖尿病%超声
阿卡波糖%急性冠脈綜閤徵%頸動脈斑塊%2型糖尿病%超聲
아잡파당%급성관맥종합정%경동맥반괴%2형당뇨병%초성
Carotid arteries%C-reactive protein%Plaque vulnerability%Type 2 diabetes mellitus%Ultrasound
目的:对合并2型糖尿病(T2DM)的急性冠脉综合征(ACS)患者进行超声检查,评估颈动脉斑块回声增强,确定阿卡波糖是否可以迅速稳定不稳定的动脉斑块。方法连续性选入于2010年10月~2013年2月就诊于本院的合并T2DM的ACS患者且同时有颈动脉斑块的132例患者,将其随机分入阿卡波糖治疗组(150 or 300 mg/d, n=66)和对照组(n=66)。ACS患者于发病5 d内行阿卡波糖治疗。通过颈动脉超声以及整合背向散射技术测量斑块回声增强,评估不稳定的劲动脉斑块。治疗后2星期、1个月以及6个月内进行测量。整合背向散射指数(IBS)升高,说明颈动脉斑块回声增强。结果阿卡波糖治疗组, IBS在1个月内有显著升高,6个月内进一步升高,但对照组IBS只有少许变化。两组间差异有统计学意义(P<0.05)。同时, IBS增高与C反应蛋白水平下降密切相关。结论阿卡波糖可以改善合并T2DM的ACS患者的颈动脉斑块回声的增强。
目的:對閤併2型糖尿病(T2DM)的急性冠脈綜閤徵(ACS)患者進行超聲檢查,評估頸動脈斑塊迴聲增彊,確定阿卡波糖是否可以迅速穩定不穩定的動脈斑塊。方法連續性選入于2010年10月~2013年2月就診于本院的閤併T2DM的ACS患者且同時有頸動脈斑塊的132例患者,將其隨機分入阿卡波糖治療組(150 or 300 mg/d, n=66)和對照組(n=66)。ACS患者于髮病5 d內行阿卡波糖治療。通過頸動脈超聲以及整閤揹嚮散射技術測量斑塊迴聲增彊,評估不穩定的勁動脈斑塊。治療後2星期、1箇月以及6箇月內進行測量。整閤揹嚮散射指數(IBS)升高,說明頸動脈斑塊迴聲增彊。結果阿卡波糖治療組, IBS在1箇月內有顯著升高,6箇月內進一步升高,但對照組IBS隻有少許變化。兩組間差異有統計學意義(P<0.05)。同時, IBS增高與C反應蛋白水平下降密切相關。結論阿卡波糖可以改善閤併T2DM的ACS患者的頸動脈斑塊迴聲的增彊。
목적:대합병2형당뇨병(T2DM)적급성관맥종합정(ACS)환자진행초성검사,평고경동맥반괴회성증강,학정아잡파당시부가이신속은정불은정적동맥반괴。방법련속성선입우2010년10월~2013년2월취진우본원적합병T2DM적ACS환자차동시유경동맥반괴적132례환자,장기수궤분입아잡파당치료조(150 or 300 mg/d, n=66)화대조조(n=66)。ACS환자우발병5 d내행아잡파당치료。통과경동맥초성이급정합배향산사기술측량반괴회성증강,평고불은정적경동맥반괴。치료후2성기、1개월이급6개월내진행측량。정합배향산사지수(IBS)승고,설명경동맥반괴회성증강。결과아잡파당치료조, IBS재1개월내유현저승고,6개월내진일보승고,단대조조IBS지유소허변화。량조간차이유통계학의의(P<0.05)。동시, IBS증고여C반응단백수평하강밀절상관。결론아잡파당가이개선합병T2DM적ACS환자적경동맥반괴회성적증강。
Objective To evaluated carotid artery plaque echolucency using ultrasound in patients with ACS and type 2 diabetes mellitus (T2DM) to determine whether acarbose may rapidly stabilize unstable atherosclerotic plaques.Methods ACS patients with T2DM and carotid plaques (n=132) were randomly assigned to treatment with acarbose (150 or 300 mg/d, n=66) or a control group (no acarbose, n=66). Acarbose treatment was initiated within 5 days after the onset of ACS. Unstable carotid plaques were assessed by measuring plaque echolucency using carotid ultrasound with integrated backscatter (IBS) before, and at 2 weeks, 1 month and 6 months after the initiation of treatment. An increase in the IBS value reflected an increase in carotid plaque echogenicity.Results IBS value of echolucent carotid plaques showed a significant increase at 1 month and a further increase at 6 months after treatment in the acarbose group, but there was minimal change in the control group. The increase in IBS values was significantly correlated with a decrease in C-reactive protein levels. Conclusion Acarbose rapidly improves carotid plaque echolucency within 1 month of therapy in patients with ACS and T2DM.